The short answer
Synthetic peptides are built stepwise and their characteristic impurities are deletion sequences (chains missing a residue). Recombinant proteins are expressed in living cells and their characteristic impurities are host cell proteins, host DNA, endotoxin and misfolded isomers. These require entirely different testing.
Key facts
- Synthetic route
- Solid-phase, stepwise coupling
- Synthetic impurities
- Deletion sequences, truncations
- Recombinant route
- Expression in host cells
- Recombinant impurities
- Host protein, DNA, endotoxin
- Also possible
- Misfolded disulfide isomers
- IGF-1 LR3 route
- Recombinant
How a synthetic peptide fails
Solid-phase synthesis adds one residue at a time, and each coupling is slightly less than complete. The failures accumulate as deletion sequences, chains identical to the target but missing a residue. At 99% efficiency per step a 39-residue peptide finishes around 68% full-length. These impurities differ from the target by one residue's mass and are detectable by mass spectrometry.
How a recombinant protein fails
Living cells build the protein correctly or not at all. There are no deletion sequences, because ribosomal synthesis does not partially fail that way. What contaminates the product instead is everything else the host cell contained: its own proteins, its DNA, and in bacterial systems endotoxin from the cell wall. Purification removes most but never all.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
Why endotoxin is its own category
Endotoxin is a bacterial cell wall component that provokes strong biological responses at very low concentrations. It is not a protein and does not appear in a protein purity figure at all. It requires its own assay, and for a recombinant protein expressed in bacteria it is a standard specification rather than an optional extra.
The folding problem on top
Correct amino acid sequence does not guarantee correct three-dimensional structure. For a protein with three disulfide bonds, misfolded isomers have identical mass and identical composition. They differ only in which cysteines paired with which. No purity figure and no mass spectrum distinguishes them.
What a certificate should therefore show
For a synthetic peptide: purity by HPLC, mass by MS, net peptide content, water and counter-ion content. For a recombinant protein: purity, host cell protein, host DNA, endotoxin, and ideally something addressing conformation or biological activity. A certificate for a recombinant protein that reads exactly like a synthetic peptide's is testing for the wrong failures.
The practical consequence
Reading an IGF-1 LR3 certificate with synthetic-peptide expectations means checking for problems this production route does not have, while not checking for the ones it does. It is the single most useful thing to understand about this category.
Quick reference
| Synthetic peptide | Recombinant protein | |
|---|---|---|
| Built by | Stepwise chemistry | Living host cells |
| Main impurity | Deletion sequences | Host protein, DNA, endotoxin |
| Folding risk | Minimal | Real (disulfide isomers) |
| Detectable by MS | Yes | Misfolds are not |
Frequently asked questions
Do recombinant proteins have deletion sequences?
No. Ribosomal synthesis does not partially fail that way. The protein is built correctly or not at all.
What is endotoxin and why test for it?
A bacterial cell wall component that provokes strong biological responses at low concentrations. It does not appear in a protein purity figure and needs its own assay.
Can a purity figure tell me the protein is folded correctly?
No. Misfolded disulfide isomers have identical mass and composition. Only the cysteine pairing differs.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLi T et al., Production and characterization of highly purified recombinant thymosin beta 4. Protein Expr Purif 2013 (PMID 23711379)pubmed.ncbi.nlm.nih.gov
- PubMedChamberlain P et al., Immunogenicity risk assessment for an engineered human cytokine analogue. AAPS J 2020 (PMID 32291556)pubmed.ncbi.nlm.nih.gov
- PubMedMilner SJ et al. Biochem J 1995 (PMID 8948444)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- IGF-1 LR3 Against the Native Hormone70 residues against 83, and a completely different relationship with binding proteins. Why one is an approved medicine and the other is not.
- Why LR3 Exists: The Cell Culture ApplicationCultured cells secrete their own binding proteins, which sequester added IGF-1 unpredictably. An analogue that resists them gives consistent availability.
- IGF-1 LR3 Storage: A Folded Protein, Not a PeptideA folded protein can lose activity while remaining chemically intact. Why denaturation and adsorption matter more here than chemical degradation.
- How to Verify a Protein With No PubChem RecordIGF-1 is not in PubChem - proteins are indexed in UniProt instead. What that means for checking a certificate, and what a certificate should carry.
- IGF-1 LR3 and Anti-Doping StatusIGF-1 and its analogues sit in WADA class S2, prohibited in and out of competition. What that classification covers and why it is unconditional.